IL33 and neoplasm: IL-33 blockade restricted SCC outgrowth, decreased Th2-derived IL-4 and increased the accumulation of Th1 IFNγ-producing cells in tumour-draining lymph nodes, and thus represents a promising SCC treatment strategy (Fig. 4).